Clinical research and trials in the Australia and New Zealand region offer foreign companies an opportunity to collaborate with local institutions, tap into diverse patient populations, access high-quality healthcare infrastructure, and gain regulatory approvals, enabling them to expand their market reach and accelerate the development of innovative medical interventions.

Clinical trials continued in Australia and New Zealand during lockdown, thanks to collaboration between industry and government, allowing the region to attract trials from other countries.

Clinical research and trials in the Australia and New Zealand region offer foreign companies an opportunity to collaborate with local institutions, tap into diverse patient populations, access high-quality healthcare infrastructure, and gain regulatory approvals, enabling them to expand their market reach and accelerate the development of innovative medical interventions.

Clinical trials continued in Australia and New Zealand during lockdown, thanks to collaboration between industry and government, allowing the region to attract trials from other countries.

Mechoulam was possibly the most significant academic to shed light on the active principles of the cannabis plant back in the 1960s, when his work at the Weizmann Institute led to the discovery of the human endo-cannabinoid system, giving him the title the “Godfather of cannabis research”. In a recent Global Health Talk with Michael Lesner, Professor Mechoulam reflects on his lifelong work in cannabis research.

The Asia Pacific Medical Technology Association (APACMed) represents manufacturers and suppliers of medical equipment, devices and in-vitro diagnostics, industry associations and other key stakeholders associated with the medical technology industry in Asia Pacific.